Wanbury Ltd., a trusted name in the pharmaceutical industry, is set to launch two new products catering to the formulation and API segments. The company introduces WANBURY C-RED, a branded hematinic iron tablet, and Ketamine Hydrochloride, an API (bulk drug) for the global market.
WANBURY C-RED
With a strong presence in the gynecology segment, Wanbury is launching WANBURY C-RED, a superior iron supplement to combat iron deficiency and improve hemoglobin levels, especially during pregnancy. Given that over 40% of Indians suffer from anemia, the demand for high-quality iron supplements is significant.
This liposomal iron formulation offers better absorption, prevents gastric irritation and constipation, and ensures quick hemoglobin rise with excellent safety and tolerability. Wanbury previously had the well-known C Pink brand, which was divested during debt restructuring.
Ketamine Hydrochloride
Wanbury’s Ketamine Hydrochloride is developed through an innovative, cost-effective process by its in-house R&D team, complying with USP and EP pharmacopeia standards. With an annual demand exceeding 200 tons in human and veterinary applications, Ketamine is a widely used anesthetic that induces sleep before and during surgeries.
The company will commence Ketamine exports to European markets this month, strengthening its global footprint in the API segment.
